Dogwood Therapeutics, Inc. (DWTX)Healthcare | Biotechnology | Alpharetta, United States | NasdaqCM
2.65 USD
+0.33
(14.224%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.65 |
Hot Take ↕ | Aug. 22, 2026, 5:30 a.m. EDT
The immediate outlook is clouded by a severe multi-year structural decline. Despite a recent bounce in price, the underlying business has suffered three consecutive years of negative annual returns, culminating in a catastrophic 96% drop over the last four years. This trajectory suggests the market has permanently reassessed the company's viability, rendering any short-term technical recovery highly suspect. Fundamentally, the picture is dire: the company is burning through cash with significant negative free cash flow, negative returns on both assets and equity, and no path to profitability indicated by negative forward earnings estimates. While the balance sheet currently shows low debt relative to equity, this is likely propped up by minimal assets given the massive cash burn, creating a precarious situation where capital preservation is the only priority. There is no dividend to provide income, and the lack of a track record of positive growth makes a 'buy and hold' strategy perilous. The recent news of clinical milestones offers hope for a turnaround, but until the company demonstrates sustained revenue growth and margin expansion, the investment case remains overwhelmingly bearish. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.181481 |
| MSTL | 0.183898 |
| AutoETS | 0.188799 |
| AutoARIMA | 0.189797 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 29.39 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.089 |
| Excess Kurtosis | -0.72 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.186 |
| Market Cap | 90,080,264 |
| Trailing P/E | 1.24 |
| Forward P/E | -0.42 |
| Beta | 1.76 |
| Previous Name | Virios Therapeutics, LLC |
| Website | https://dwtx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5176715 |
| Address1 | 44 Milton Avenue |
| All Time High | 417.75 |
| All Time Low | 1.28 |
| Ask | 3.03 |
| Ask Size | 2 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 87,630 |
| Average Daily Volume3 Month | 77,270 |
| Average Volume | 77,270 |
| Average Volume10Days | 87,630 |
| Beta | 1.762 |
| Bid | 1.85 |
| Bid Size | 2 |
| Book Value | 2.033 |
| City | Alpharetta |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.65 |
| Current Ratio | 3.894 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.69 |
| Day Low | 2.36 |
| Debt To Equity | 0.186 |
| Display Name | Dogwood Therapeutics |
| Earnings Call Timestamp End | 1,730,986,200 |
| Earnings Call Timestamp Start | 1,730,986,200 |
| Earnings Timestamp End | 1,778,761,800 |
| Earnings Timestamp Start | 1,778,761,800 |
| Ebitda | -29,558,684 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.727 |
| Enterprise Value | 80,597,440 |
| Eps Forward | -6.37 |
| Eps Trailing Twelve Months | 2.13 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.7298 |
| Fifty Day Average Change | 0.9202001 |
| Fifty Day Average Change Percent | 0.5319691 |
| Fifty Two Week Change Percent | -51.76715 |
| Fifty Two Week High | 9.5 |
| Fifty Two Week High Change | -6.85 |
| Fifty Two Week High Change Percent | -0.72105265 |
| Fifty Two Week Low | 1.28 |
| Fifty Two Week Low Change | 1.3700001 |
| Fifty Two Week Low Change Percent | 1.0703126 |
| Fifty Two Week Range | 1.28 - 9.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,608,215,400,000 |
| Float Shares | 5,810,007 |
| Forward Eps | -6.37 |
| Forward P E | -0.4160126 |
| Free Cashflow | -16,359,929 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 8 |
| Fullday Change | 0.33 |
| Fullday Change Percent | 14.2241 |
| Fullday Price | 2.65 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.72569 |
| Held Percent Institutions | 0.114700004 |
| Implied Shares Outstanding | 33,992,553 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,728,432,000 |
| Last Split Factor | 1:25 |
| Long Business Summary | Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia. |
| Long Name | Dogwood Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 90,080,264 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_204765942 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-29 |
| Net Income To Common | -36,041,288 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 78,862,722 |
| Number Of Analyst Opinions | 3 |
| Open | 2.36 |
| Operating Cashflow | -15,108,253 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 866 620 8655 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.65 |
| Post Market Time | 1,787,960,001 |
| Prev Name | Virios Therapeutics, LLC |
| Previous Close | 2.32 |
| Price Hint | 4 |
| Price To Book | 1.3034924 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.394 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 0.33 |
| Regular Market Change Percent | 14.2241 |
| Regular Market Day High | 2.69 |
| Regular Market Day Low | 2.36 |
| Regular Market Day Range | 2.36 - 2.69 |
| Regular Market Open | 2.36 |
| Regular Market Previous Close | 2.32 |
| Regular Market Price | 2.65 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 133,665 |
| Return On Assets | -0.20831 |
| Return On Equity | -0.47766 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 33,992,553 |
| Shares Percent Shares Out | 0.0015 |
| Shares Short | 49,958 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 73,016 |
| Short Name | Dogwood Therapeutics, Inc. |
| Short Percent Of Float | 0.0041 |
| Short Ratio | 1.02 |
| Source Interval | 15 |
| State | GA |
| Symbol | DWTX |
| Target High Price | 15.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 14.0 |
| Target Median Price | 15.0 |
| Total Cash | 9,610,033 |
| Total Cash Per Share | 0.283 |
| Total Debt | 127,208 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.13 |
| Trailing P E | 1.2441314 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.81046 |
| Two Hundred Day Average Change | -0.16046 |
| Two Hundred Day Average Change Percent | -0.05709385 |
| Type Disp | Equity |
| Volume | 133,665 |
| Website | https://dwtx.com |
| Zip | 30,009 |